15th Asia-Pacific Australian Prostate Cancer Prostate Cancer Conference 2014 Research
31 AUGUST - 2 SEPTEMBER 2014 MELBOURNE CONVENTION AND EXHIBITION CENTRE Melbourne, Australia
CLINICAL UROLOGY | TRANSLATIONAL SCIENCE | NURSING & ALLIED HEALTH
Conference Program
Follow us on twitter www.prostatecancerconference.org.au #apcc14 @AustProstate
Sponsors and Partners
We thank our Sponsors and Partners for their support. Principal Sponsor
Gold Sponsors
Silver Sponsors
Breakfast Sponsors Satellite Evening Session Sponsor
Translational Science Clinical Urology
Welcome Reception and Lanyard and Name da Vinci Masterclass Poster Awards Sponsor Badge Sponsor Sponsors age 3 P Contents Welcome!
Welcome 4 Welcome to the 15th Asia-Pacic Prostate Host and Committees 6 Cancer Conference. We are proud to again International Speakers 8-9 bring the world's experts together and National Speakers 10 celebrate 15 years of industry education this year. Program Sunday 31st August 11-12 2014 brings with it a number of new Monday 1st September 12-15 educational opportunities for attendees, Tuesday 2nd September 16-17 including the MRI Masterclass, which sold Janssen Satellite Symposium 19 out swiftly. As always, the Conference will empower our health care industry to Posters implement improved patient care practices Clinical Urology 20-21 and provide up to date information for Nursing & Allied Health 22-23 patients to make informed choices. Translational Science 24 Men's health will feature more broadly this Clinical Urology Meeting 25 year, with opinion leaders addressing the lag Nursing & Allied Health 26-27 in specialist services for men. The program Translational Science Program 28 also includes specialised meetings for all Masterclasses 29-31 practitioners involved in prostate cancer care Social Program 32 delivery including: Urologists, Radiologists Registration Information 33 Radiation Oncologists, Medical Oncologists, Presentation Information 34 Researchers, Nurses, General Practitioners, Melbourne 34-35 Psycho-Oncologists, Physiotherapists and General Information 36 more. Exhibition Information 37-38 Exhibitor Proles 39-45 We look forward to welcoming you in coming together as an industry for this international event in Melbourne. Thank you for participating and we hope you nd the 15th Asia-Pacic Prostate Cancer Conference informative and inspiring. Prof Tony Costello President, 15th Asia-Pacic Prostate Cancer Conference Executive Director, Australian Prostate Cancer Research
15th Asia-Pacific Prostate Cancer age 4 Conference 2014 P
15th Asia-Pacific Prostate Cancer Conference 2014
Australian Prostate Cancer Research is a national research organisation that partners with leading institutions to develop, fund and deliver national research programs. We are committed and driven to discover the cause of prostate cancer, improve patient outcomes and educate people on all aspects of diagnosis, treatment and patient care, thereby empowering men and their families. www.prostatecancerresearch.org.au
Australian Prostate Cancer Nursing & Allied Health Stream Research would like to thank the Convenors following individuals for their Ms Helen Crowe involvement in the 15th Asia-Pacic Prostate Cancer Nurse Practitioner, Prostate Cancer Conference. Research Nurse, Epworth Prostate Centre Asia-Pacic Prostate Cancer Conference – Founder & Dr Addie Wootten Convenor Clinical Psychologist, Department of Prof Anthony Costello Urology, The Royal Melbourne Executive Director, Australian Prostate Hospital. Director of Clinical & Allied Cancer Research, Director of Health Research, Epworth Prostate Urology, Royal Melbourne Hospital Centre, eHealth Research Manager; Australian Prostate Cancer Research Local Organising Committee Dr Jane Crowe Program Secretary Private General Practitioner & Dr Phil Dundee Prostate Cancer Physician, Epworth Royal Melbourne Hospital, Western Prostate Centre General Hospital, Epworth Prostate Centre Mr James Garland CEO, Australian Prostate Cancer Clinical Urology Stream Convenor Research A/Prof Declan Murphy Urologist and Director of Robotic Mrs Sally Marasco Surgery, Peter MacCallum Cancer Business Development Manager, Centre, Epworth Prostate Centre Australian Prostate Cancer Research, Conference Manager Translational Science Convenors Dr David Sandall We are also grateful for the support of Chief Operating Ofcer, Epworth the program stream sub committee Prostate Centre, members whom are acknowledged on the program stream page. Prof John Mills Director of Research and Development, TissuPath Specialist Pathology age 6 P
Page 8 I n t e r n a Mr P Dr P Prof JelleBarentsz Dr MitchellBenson Dr MatthewCooperberg Centre Comprehensive Cancer Diller F San F University ofCalifornia, Epidemiology &Biostatics, A/Prof (USA) London St Bartholomew’sHospital Prostate CancerLead– Surgeon Consultant Urological Genito-urinary Oncology Senior Lecturerin (UK) of UrologyatUC F (USA) Department ofRadiology Medical Centre Radbound University (Netherlands) Department ofUrology former Chairofthe Columbia Universityand Urology facultyat (USA) aculty intheDepartment t eter Carroll rancisco, Helen aul Cathcart , DeptsofUrology& i amily o n a SF l S p e a k e r s Mr ThomasL Prof RogerKirby Prof LarryGoldenberg Mr MarkusGraefen Dr JohnDavis Dr JuanitaCrook College, Dublin Hospital andT Surgeon atSt.James’s Consultant Urological (Ireland) Centre Director ofTheProstate Consultant Urologist, (UK) British Columbia Sciences, Universityof Department ofUrologic Professor andHead, (Canada) University ofHamburg Cancer Centeratthe Martini-Clinic, Prostate (USA) Anderson CancerCenter surgery programatMD the prostatecancer Urology andDirectorof Associate Professorof (Netherlands) K (Canada) elowna GeneralHospital Conference P A 15th r s o i a s - t rinity P a t a ynch e c i C fi a c n 2014 c e r I n t e r n a Dr MatthewSmith Dr ChristianNelson Medical School Medicine atHarvard Hospital andProfessorof Massachusetts General Malignancies Programat Genitourinary Director ofthe (USA) medicine services genitourinary andsexual Memorial SloanK P (USA) sychological liaisonto t i o n a ettering’s l S p e a k e r s Prof BertrandT Dr HenkvanderP the DivisionofUrology Chairman of (Belgium) Institute Netherlands Cancer Department ofUrology (Netherlands) Saint Cliniques Universitaires c o n -Luc, Brussels t i n u e d ombal , , oel
Page 9 Page 10 N Dr PrueCormie Prof RobertNewton A/Prof NathanLawrentschuk Dr JoeIschia A/Prof ChrisHovens Mr JeremyGrummet Prof DanielGalveo Prof MarkF Dr P Dr ArunAzad Institute Health andW Health andW P Edith CowanUniversity Department ofSurgery Austin Health Centre The UniversityofMelbourne,EpworthProstate Australian UrologyAssociates Edith CowanUniversity Surgery Medical Centre;Chairman,InstituteofSpecialty Chairman, DepartmentofUrology Edith CowanUniversity Director ofEpworthRadiationOncology British ColumbiaCancerAgency eter MacCallumCancerCentre a at Bowden t , EpworthHealthcare i o Conference P A 15th rydenberg ellness Institute ellness Institute r s o i a n s - t P a a t a e c , AustinHospital; , HealthandW , , i C fi l S a c n 2014 c e r p , Monash e ellness a k e r s Dr MaxRutherford Dr BenT Ms KayT Dr R Dr ShomikSengupta Dr P Dr AddieW Ms SarahW A/Prof ScottW Mr MarkT The RoyalMelbourneHospital Australian UrologyAssociates The UniversityofQueensland The AustinHospital P The RoyalMelbourneHospital The P Australian ProstateCancerResearch Independent Researcher P Health andW Edith CowanUniversity A/Prof P eter MacCallumCancerCentre eter MacCallumCancerCentre atricia Neumann yan Stafford elvic FloorClinic enelope Schofield ran albot revaskis ootten ellness Institute oollet illiams , Conference P A 15th r s o i a s - t P a t a e c i C fi a c n 2014 c e r S 1330 1230- 1030 1000- 1230 1030- 0800 u
pr See page29forfull pr See page29forfull R Masterclass R Masterclass See page29forfullpr P 4th daVinci P 4th daVinci R 4th daVinciP L MORNING TEA n Clinical Ur UNCH oom 219 oom 219 oom 219 rostatectomy rostatectomy ogram details ogram details d ology a rostatectomy Masterclass y 3 T ranslational Science ogram details pr See page31forfull pr See page31forfull R Masterclass Brachytherapy LDR R Masterclass Brachytherapy LDR oom 218 oom 218 ogram details ogram details 1 s t A Nursing &AlliedHealth pr See page30forfull pr See page30forfull R Masterclass Imaging &Biopsy R Masterclass Imaging &Biopsy P P oom 220 oom 220 rostate MRI rostate MRI ogram details ogram details u g u s Pr 1330 1410 Jane Cr Deprivation Therapy:Managingthesideeffects | 1345 1030 scene: Abriefoverview| Mark Frydenber management pr suppor 1435 Christian Nelson W Active Sur Nursing &AlliedHealth Chairs: ShanMorrisonandAdamL Plenary 3 Continence Nursing &AlliedHealth Chairs: AddieW Plenary 3 Hor Nursing &AlliedHealth 0805 1100 Ryan Staffor Chairs: KayT Plenary 3 0800 T 0830 incontinence | implications forthepatient:T 1130 pr 0900 0930 | 1200 Active Surveillance| Daniel Galveo P P rish Neumann otential ApplicationofExer anel discussionwithRogerKirby ostate sur atchful W t 2 Jer ue Cormie mone Therapy emy Gr Andr Thecognitiveimpactof hormonetherapy| ThephysiologicalimpactofAndr Settingthescene,ActiveSurveillanceversus Impr
Anoverviewofbiopsytechniquesand
Thepersonalandpsychosocialexperiencesof
Theimpactofincontinenceonsexualintimacy| ActiveSurveillanceforPr Qualitative experiencesofpatientswith W Dynamics ofthemalepelvicfloor T eaching pelvicfloorexer t gr owe elcome | oup tailor oving mentalwellbeing thr ogen DeprivationTherapy veillance aiting andanoverviewofthecurr gery –whatisbestpractice? d ummet albot andP 0 otocols forActiveSurveillance| Sarah Woollet g ootten andR Addie WoottenandHelenCr ed formenwith pr 1 P enelope Schofield 4 aul Cathcar HelenCr cise Medicine| ober ransperineal versusTRUS ostate Cancer– cises tomenbefor t Newton owe andKayT andau t , Settingthe ough exer ostate cancer | ogen | | ent
owe cise: a albot e
Page 11 Sunday 31st August 2014
1500- AFTERNOON TEA 1530
1530- 4th da Vinci LDR Prostate MRI Nursing & Allied Health 1700 Prostatectomy Brachytherapy Imaging & Biopsy Advanced prostate cancer Masterclass Masterclass Masterclass Plenary 3 Room 219 Room 218 Room 220 Chairs: Helen Crowe and Phil Dundee See page 29 for full See page 31 for full See page 30 for full 1530 Reflections upon the provision of psychological program details program details program details support to men with Advanced Prostate Cancer | Max Rutherford 1550 New radiation therapy techniques for advanced prostate cancer | Pat Bowden 1610 New systemic treatments and agents for advanced prostate cancer | Ben Tran 1630 Panel discussion – the challenges of managing and supporting the complex advanced prostate cancer patient | Panel 1650 Discussion of resources available and how to access them 1655 Meeting close Addie Wootten & Helen Crowe
1700- Poster and Welcome Reception 1900 Exhibition Area
Monday 1st September 2014
0745- Combined Multidisciplinary Plenary 0800 Plenary 3 Chair: Tony Costello, Roger Kirby, Larry Goldenberg 0745 Conference Opening & Welcome | Prof Tony Costello 0800 Ministerial Address | Hon. Peter Dutton MP 0815 Men's Health: The Final Piece of the Puzzle of Family Health | Larry Goldenberg 0835 The trouble with men | Roger Kirby 0840 Life without PSA testing – future predictions if the USPSTF had their way | Matthew Cooperberg 0855 Characterisation of a high volume center for radical prostatectomy – perspectives beyond surgical expertise | Markus Graefen 0910 State-of-the-Art mp-MRI: clinical role and PI-RADS reporting | Jelle Barentsz 0925 The timing of androgen deprivation therapy – new perspectives in 2014 | Bertrand Tombal 0940 Optimal timing and sequencing of new androgen pathway inhibitors in castration-resistant prostate cancer | Matthew Smith 0955 Questions 0958 Prostate Cancer World Congress 2015 Announcement
1000- MORNING TEA 1030 age 12 P Clinical Urology Translational Science Nursing & Allied Health M 1230 1030- o | assessment leadstor R 1200 Intr 1150 Ben T in low 1135 oligometastatic disease| 1120 Markus Graefen in metastasizedpr 1105 Jelle Bar 1050 Scott W oligometastatic disease| 1035 1030 Chair: DeclanMurphy Plenary 3 Oligometastatic disease Clinical Ur efined pr P oduction | eter Carr n 2ndP 2ndP Thechoiceofsystemictherapies Ster Ther NodalImagingr Themolecularimagingof Intr ran -volume metastaticdisease| illiams d entsz oduction | eotactic radiotherapyfor ostate cancerrisk ology ole ofradicalpr atrick CW atrick CW oll a T ony Costello ostate cancer| y 1 T Declan Murphy ranslational Science efined tr , JosephBucci evisited | alsh L alsh L P
ostatecomy at Bowden ectur ectur s eatment e: e –
t S Cancer | T New Causes:Identif 1030 Chair: Pr R Therapies 1045 activator oftheaminoacidstr 1100 cells r andr 1115 Michelle Liberio topoisomerase IIinLNCaPcells pathways thr activates DNAdamager | Gr 1205 chemotherapy outcomeofpr associated withdocetaxel 1130 pr 1145 r cancer endemic rainfor compounds isolatedfr pr esponse pathwayinpr esistance r oom 218 eatments forMetastaticPr ostate cancermetastasisandtherapy ostate cancercellsonnew Nursing &AlliedHealth ogen signallinginpr egor T |MichelleLiberio e R BDX1:Anaturalsmallmolecule TheAscidiannaturalpr Co-tar Cir Mechanismofactionstudiesin T |Hui-MingLin ar epositioning "Old"Drugsfor of ColleenNelson geting neur culating micr Esha Shah |Br p evz geting H2r ough inhibitionof ett Hollier t est tr e ying New opilin-1 toinhibit ee oRNAs om anAustralian |Clair ostate cancer elaxin and esponse m ostate cancer ostate ostate oduct EB ess e L | evrier b
e ADT forpr and physicalactivitypr R Cur varying exer 1120 Christopher Thomas pr who havecompletedtr 1030 Nelson R depr 1130 | randomized contr markers ofcar r 1040 intervention formenwithpr Ahead: Anonlinepsychological Chairs: R cancer patients? pr and urinaryfunctionofgaystraight Advanced Pr r P pr Pr specific LivingwithCancerEducation Cancer: Thedevelopmentofatumour cancer 1110 11 Best OralP 1150 | P with verbalinstruction-domengetit? L pr 1050 1100 1220 ADT with pr pr and physiologicaloutcomesfor r 1200 1210 Steve Fraser eferr eally adiffer eferr eah Zajdlewicz atrick Owen oom 220 esearch T r 2 ostate cancer:Amulticentr ostate cancersurvivors:Isther ostate cancersurvivors ogram onfitness,bodycomposition ostate cancersurvivors P ogram 40 atricia Livingston atricia Neumann rent NursingandAlliedHealth |BradleyW ession inadequateforpr ed exer ed supervisedexer R Effectsofaclinician Ar Theefficacyofaclinician Self P P Pr EngagingMenwithPr Theefficacyofaclinician Maximalexer Discussion andpr |AddieWootten ostate cancerbeingtr elvic Floormusclecontraction sychological Distr eduction offatigueinmenon eliminary r e curr |DavidGray ober -esteem, bodyimage,sexual ostate cancer:effectof aper prize rends cise modes cise trainingpr ostate Cancer ence? t NewtonandChristian ent definitionsof diometabolic riskfor 0 |VickiBitsika all olled trial[ENGAGE] esults ofMyR cise testingofmen | 1 eatment for ogram formen |DennisT 4 cise training esentation of | ess and | ’s r | ogram on ostate ostate eated with ostate e cluster eferral e oad aaffe
Page 13 Page 14 M 1530 1500- 1330 1230- 1500 1330- o 1455 for howlong| stage pr 1440 Mitchell Benson pr 1425 Nathan Lawr pendulum swungtoofar?| 1420 Shomik Sengupta pr 1410 Jer transperineal pr experience | 1400 Pr 1345 Jer 1330 Frydenber pr P L AFTERNOON TEA Chair: NathanL Plenary 3 and ActiveSur UNCH Clinical Ur atter ostate cancerr ostate biopsyisfine| ostate cancerdiagnosisinVictoria| ostate CancerAudit–theEnglish emy Gr emy Millar n Questions&Answers| Activesurveillanceforearly Isactivesurveillanceforlowrisk Activesurveillance–hasthe P P HowwesetupaNational P ns ofCare,RiskStratication oint-counterpoint: TRUS oint-counterpoint: wemustdo atterns ofcar ostate cancer–who,howand d g ummet ology entschuk P a aul Cathcart P awr ostate biopsy| veillance eter Carr eally safe?| entschuk, Mark y 1 T e formenwitha ranslational Science
oll
s
P anel
- t S Metastasis andP R Chair: Pr cancer cellsbyr migration andinvasionofpr transcription factorpr metastasis tobone| a mechanismofpr 1330 1435 mesenchymal transition| 1400 Marc Thomas (EMT) inpr epithelial-to-mesenchymal transition 1345 pr 1415 P metastasis ofpr atrick Ling oom 218 ogr Nursing &AlliedHealth e ession | Micr T Incr YB-1,adriverofpr Evading immunesurveillanceas ie-2 r of P eased expr p oRNA-194 pr ostate cancercells| egulates stemnessand amela Russell Anja Rockstr t ostate cancercells| egulating epithelial- rogression ostate cancer e ession oftheETS1 omotes Nikola Baschuk omotes m ostate cancer RajdeepDas oh ostate
b e
r 2 0 1 4 M 2330 1900- 1830 1730- 1530 o 1700 Jeff Berkley oppor 1645 P post-focal andwhole-glandHIFU| 1630 Henk V training –ERUSinitiatives| thr 1615 John Davis P 1600 Markus Graefen after radicalpr 1545 P and r P 1530 Chair: P Plenary 3 Ar Changes intheclinicalparadigmofadvancedpr Chair: LisaHorvath R Mural Hall APCC 2014ConferenceDinner R ClinicalUr atient Selection,andR aul Cathcart eter Carr eter Carr oom 218 adical P t ough modularandFellowship n obotic pr Discussion| R Salvageradicalpr OptimisingoutcomesofRARP ExtendedPLND- Impr tunities andthechallenges| P an derpoel ersonal perspectiveonopen obotic Sur eter Swindle,T d oll oll rostatectomy Stateofthe oving functionaloutcome ology a ostatectomy | ostectomy | gery Simulation:The y 1 P T anel ranslational Science T om Shannon echnique, esults | ostatectomy
s
t S
R Biomarkers andDiagnostics Chair: Pr 1530 1545 cancer | biomarkers andr Early Pr 1600 Masuda Nabi and r plasma epigeneticmarkerofpr transferase 1(mGSTP1)asapotential (CRPC). | castrate-r 1615 Damien L migration andinvasion| leading toenhancedcancercell composition oftheextracellularmatrix, poor patientoutcomebyalteringthe novel biomarkercandidatesinpr ACSM1,CACNA1D andLMNB1,thr r 1635 cancer | eceptor inpr oom 218 Nursing &AlliedHealth e esponse tochemotherapyin Cir ANovelPr Methylatedglutathiones- Over L ostate cancerinlightofemer oss ofstr ostate CancerDiagnosis| of JudithClements SaeidAlinezhad culating micr eech L esistant pr p expr uke Selth Kate Mahon ostate cancerr ession of t omal andr otein Biosensorfor egulators ofpr e ostate cancer oRNAs as m
ogen esults in ognosis ostate ostate b ee ging systemicagents| e with prostatecancer Latest exerciseprescriptionformen W R the mostuptodateexer 1530 pr clothing Pr cancer R Pre-registration required Pr Mark T Dr Pr egistrants ar oom 220 r 2 escription formenwithpr of RobNewton of DanielGalvao orkshop ue Cormie Interactive workshopexploring r evaskis e invitedtowearexer 0
1 : Interactive 4 cise ostate cise
Page 15 Page 16 T 1230 1030- 1000 0755- 0645 1030 1000- u
0955 0945 Cr 0930 0915 0900 0845 how andwhen| Ben T Bayer 1130 0815 | 1115 Sequencing oftherapiesinmetastaticpr to r Roger Kirby 1145 Chair: NathanL 0830 r 1100 early CRPC| Chair: ScottWilliams,JohnY Plenary 3 1220 Combined Multidisciplinar 1045 CRPC ChangingP MORNING TEA R 0755 BREAKF pr 1030 Chair: DanielMoon,ShahneenSandhu Plenary 3 0800 e esistant pr Clinical Ur oom 219 ostate cancer| Mitchell Benson ook espond? | Messagefr Discussion| L Standar Minimisingtheharmsofandr MSH2,pr Howdocetaxelfitsinthechanginglandscape| GenomicClassifiersforPr P CRPCcasediscussion| Andr TheUr LifeintheFastL T W Pr Scr -sponsor ran s ow doseratepr iming andmodalitiesofARtar atient selectionforabirater elcome | evention andtr AST SES eening forpr ogen r d ology ostate | ologist's r BertrandT disation ofassaymethodslimitsvariabilitytotalPSAmeasur ed br Ar awr ostate cancerandL a un Azad eceptor DNAbindingpr om PrincipalSponsorAstraZeneca| Matthew Smith MatthewSmith Chair SION entschuk aradigms eakfast session P T Mitchell Benson anel y 2 ranslational Science ostate cancer:DotheU.S.Pr ole inthetr ostate brachytherapyasaboostormonotherapy:longtermr ane –JohnFitzpatrickr eatment ofbonemetastasesin ombal y Plenar axley P ostate Cancer–HowtoEvaluateClinicalV anel eatment ofcastrate n one –whoismostlikely ynch syndr ogen deprivationtherapy| y geted agentsduring d S ostate cancer: ofiling inpr Nursing &AlliedHealth emember ome: amismatchmadeinHell?| eventive ServicesT ostate cancer| e
Christopher Goon ed | p BertrandT Therapeutic T R BREAKF R The GenomicEraofT Sanofi-sponsor Chair: A/Pr Pr mediated aminoacidtranspor 1030 1045 cancer | Helen P 1115 potential | 1100 1130 Heather Armstr shock pr 1145 signaling inLNCaPcells| pr Car 1205 castration r t oom 220 oom 218 ostate cancercellsthr of V olina Soekmadji e Henk V InvestigatingthePI3Kpathwayinpr Elucidatingthemolecularactionofsyntheticheat PTRFdecr Inhibitionoffattyacidsynthasesuppr Andr Feastinginatimeoffamine–mechanisms anessa M.Hayes Monoterpene glycoside,ESK246,tar earson ask For otein 90inhibitorsinpr AST SES Qian W m ombal ogen r of LisaHorvath esistance | Zeyad Nassar alidity vsUtility| an derP ements | argets ce (USPSTF)r ong ed br eases pr ang eceptor influencesthepr Chris Hovens b SION esults thatar eakfast session oel ranslational Medicine| Niall Corcoran e Thomas L ough exosomes| ostate cancerangiogenesis Martin Sadowski r 2 ecommendations makesense? t andcellgr John Davis ostate cancer| e har ynch d tobeat| 0 ostate cancer| oliferation of owth inpr
gets LAT3- esses andr 1
Juanita 4 ostate ogen Tuesday 2nd September 2014
1230- LUNCH 1330
1330- High-risk non-met Prostate Cancer Genetics and Epigenetics 1500 Plenary 3 Room 218 Chair: Henry Woo, James McKean Chair: Dr Niall Corcoran 1330 Management of high-risk, non-metastatic prostate 1330 Intra-metastatic heterogeneity and treatment induced cancer – are all options truly equivalent? | Peter Carroll remodelling of subclonal architecture of lethal prostate 1350 The evolution of HDR prostate brachytherapy: has it cancer | Chris Hovens come of age? | Juanita Crook 1345 Functional analysis of the KLK3 variants, found to be 1405 PLND & Fluorescence guided sentinel node imaging associated with prostate cancer risk | Srilakshmi Srinivasan for prostate cancer | Henk van der Poel 1400 Association and functional analysis of miRSNP in 1420 Management of High Risk Prostate Cancer – MD prostate cancer – results from the large collaborative Anderson approach | John Davis oncological genetics studies (COGS) | Jyotsna Batra 1435 Is intraoperative Choline Positron Emission 1415 Identification of candidate functional short tandem Tomography (PET) during robotic prostatectomy ready for repeats for analysis in large case-control prostate cancer PRIME time use: introducing the PRIME study | risk studies. | John Lai Paul Cathcart 1430 Macrophage inhibitory cytokine-1 (MIC-1/GDF15) 1450 Vancouver approach to very high-risk prostate cancer gene deletion is associated with increased tumor growth in | Joe Ischia TRAMP prostate cancer-prone mice. | Yasmin Husaini 1445 Genomic analysis of circulating tumor DNA in plasma of metastatic castration-resistant prostate cancer patients treated with abiraterone acetate and enzalutamide | Arun Azad 1505 Significance of ethnic-based disparities in prostate cancer risk and outcomes | Vanessa Hayes
1500- AFTERNOON TEA 1530
1530- Looking after men post-treatment 1700 Plenary 3 Chair: David Winkle, Phil Dundee 1530 Prostate Cancer Survivorship – improving outcomes | Matthew Smith 1545 The role of exercise in improving outcomes and quality of life for men with metastatic prostate cancer | Rob Newton 1600 The impact of surgery on erectile function and how to help men recover function | Chris Nelson 1615 Testosterone Replacement Therapy: How safe is it? | Larry Goldenberg 1630 PROSTMATE – an online platform enabling survivorship care | Addie Wootten 1645 Discussion | Panel 1655 Meeting close | Tony Costello
1700 CONFERENCE CONCLUDES age 17 Clinical Urology Translational Science Nursing & Allied Health P Page 18 Janssen Satellite Symposium Changes in the clinical paradigm of advanced prostate cancer in light of emerging systemic agents
Date: Monday 1st September 2014
Time: 17:30 – 18:30 (refreshments from 17:15)
Location: Melbourne Convention Centre
Chairs: Dr Lisa Horvath
Speakers: Dr Peter Carroll Dr Peter Carroll Dr. Peter Carroll received his The real world management of undergraduate training at the University of California, Berkeley. patients with prostate cancer After graduating with honors from Georgetown University School of Medicine, he came to UCSF for his general surgery training and urology residency. He completed a fellowship in Urologic Oncology at Memorial- Sloan Kettering Cancer Center before returning to join the faculty in the Department of Urology at UCSF. age 19 P 15th Asia-Pacific Prostate Cancer Posters Conference 2014 Clinical Urology 7 Inguinal Hernia Rates After Robot-Assisted Radical Prostatectomy: Our 5-year Weber Lau Experience at Singapore General Hospital
18 The oncological outcomes of robotic assisted radical prostatectomy in an unscreened Alvin Wei Xiang Low multi-racial Asian population
23 Emerging Trends in the Terminology of Prostate Cancer Treatment Jonathon Lo
32 Transrectal Ultrasound-Guided Prostate Biopsy Sepsis: A Worldwide Literature Review Elliot Anderson On Rates, Risk Factors And Prophylaxis
33 The cost of management for patients with metastatic prostate cancer in New Zealand Chunhuan Lao
40 Oncological Outcomes of Robotic Prostatectomy in the Victorian Public Sector Niranjan Sathianathen
42 Prostate Cancer Registry (PCR) quality of life outcomes following prostate cancer Jeremy Millar treatment
43 Satisfaction and Regret following RALP may not always reflect continence and erectile Milan Thomas function
51 Transitional experience from pure laparoscopic to robotic-assisted radical Daniel Moon prostatectomy: An Australian single surgeon series
54 Influence of variation in use of radical therapy on risk-adjusted prostate cancer mortality Paul Cathcart in England and the US
58 Comparison of Short Term Oncological and Functional Outcomes between Open and Wee Loon Ong Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the Victorian Prostate Cancer Registry
59 Extended thromboembolism prophylaxis post open radical prostatectomy is safe and Daniel Chen effective
65 Incontinence after prostatectomy is related to urethral mechanics observed with Ryan Stafford transperineal ultrasound imaging
69 Proton beam therapy websites: Characteristics and claims Sarah O'Neill
70 Practice patterns and perioperative outcomes of radical prostatectomy in Victoria: A Niranjan comparison of open, laparoscopic and robotic prostatectomy in 5130 patients over 3 Sathianathan years
72 A health economic analysis of robotic surgery in the Australian public health system Niranjan Sathianathan
73 No difference on overall survival rate between patients with prostate cancer who Untung Tranggono underwent surgical hormonal therapy and medical hormonal therapy
77 Pathways of care for metastatic prostate cancer patients in the Midland Cancer Ross Lawrenson Network, New Zealand
82 Prevention of symptomatic skeletal events in patients with genitourinary tumours and Kenneth Pittman bone metastases treated with denosumab or zoledronic acid
84 Treatment for localized prostate cancer in New Zealand men in light of clinical Zuzana Obertova guidelines
85 The burden of skeletal-related events (SREs) on pain outcomes in patients with Matthew Smith castration-resistant prostate cancer (CRPC) and bone metastases age 20 P Posters continued Clinical Urology 87 Prostate Volume Estimation in Prostate Cancer: Are Urologists or Radiologists More Steffi Yuen Accurate?
88 Transrectal ultrasound-guided biopsy with anterior needles improves detection and Arveen Kalapara localisation of prostate cancer in men undergoing active surveillance
91 Does sparing the neurovascular bundle affect urinary continence outcomes in men Fairleigh Reeves undergoing radical prostatectomy? A Systematic Review
94 The utilisation of Active Surveillance in a Victorian cohort of men, according to PRIAS Mahesha Weerakoon and other contemporary Active Surveillance protocols
107 Current use of Active Surveillance in Victoria, Australia: a patterns of care analysis from Mahesha Weerakoon the Prostate Cancer Registry
108 Clinical use of a novel technique for ablation of prostate cancer, irreversible Jeremy Millar electroporation (IRE), and characterisation of the resulting prostate pathology
110 The APCCR: beginning a global journey towards international benchmarking of Sue Evans prostate cancer outcomes
113 Validation of the relationship between urethral motion measured with transurethral Paul Hodges ultrasound imaging and activation of the striated muscle complexes of the male pelvic floor
118 Stereotactic body radiotherapy for oligometastatic prostate cancer: Retrospective Fairleigh Reeves series from a single Australian centre
128 Biological imaging for focal brachytherapy for prostate cancer Scott Williams
131 Surgical outcomes of patients who fail active surveillance for localised prostate cancer Arveen Kalapara in an Australian population
139 Prostate cancer in the elderly in Morocco: a retrospective review Hinde Hami
141 Prostate cancer in Niger: first results from a population-based cancer registry Hinde Hami
143 Results of surgical treatment of patients with clinically insignificant prostate cancer Kirill Nyushko classified according Epstein criteria
144 Outcome prognostic factors in prostate cancer patients after surgical treatment Kirill Nyushko
158 Practice patterns of urologists in managing Korean males 40 years old or younger with Dae-Seon Yoo high serum PSA levels
160 An initial Melbourne experience of multiparametric MRI for the diagnosis of prostate Sarah O’Neil cancer
161 Does transperineal biopsy cause erectile dysfunction? Jeremy Grummet
162 Radical prostatectomy without prostate biopsy in PIRADS 5 lesion on 3T multi- Andrew Keller parametric MRI of the prostate gland: 2 Case Reports
167 Zero sepsis in 452 consecutive transperineal biopsies: an update on the VTBC Jeremy Grummet database
172 Evaluation of models predicting insignificant prostate cancer to select men for active Lih-Ming Wong surveillance of prostate cancer
173 A comparison of two novel methods of analgesia for transrectal ultrasonography Sean Huang (TRUS)-guided prostate biopsy – Penthrox alone versus Penthrox plus periprostatic
infiltration of local analgesia age 21 P 15th Asia-Pacific Prostate Cancer Posters continued Conference 2014 Nursing & Allied Health 10 Working with Grieving Adults: The Relevance of Attachment to Coping Styles John Toussaint
17 Trajectory of pain following open and minimally invasive radical prostatectomy for Damien Khaw localised prostate cancer: An Australian multi-site, comparative study
19 Baseline characteristics of the participants in a telephone-delivered mindfulness Robert McDowall intervention for men with advanced prostate cancer
20 Preliminary results of My Road Ahead: An online psychological intervention for men Addie Wootten with prostate cancer
22 Effects of a clinician’s referral and physical activity program for men who have Patricia Livingston completed treatment for prostate cancer: A multicentre cluster randomized controlled trial [ENGAGE]
24 Evaluation of the Outreach Clinics of the Prostate Cancer Specialist Nurse in Tamworth, Sharon Slack NSW
31 PROSPECT: Understanding how multiple factors interact to predict depression in Chris Sharpley prostate cancer patients and their partners during the first year after diagnosis
34 Are current definitions of depression inadequate for prostate cancer patients? Vicki Bitsika
36 Engaging Men with Prostate Cancer: The development of a tumour specific Living with David Gray Cancer Education Program
38 Rethinking the DRE: Introducing novel non-invasive tests of pelvic floor muscle function Jo Milios in humans
45 Self esteem, body image, sexual and urinary function of gay and straight prostate Christopher Thomas cancer survivors: Is there really a difference?
46 Designing New Health Services for Advanced Prostate Cancer Patients: Challenges Amol Wagholikar and Opportunities
47 The prevalence of depressive symptoms among patients undergoing low and high David Christie dose-rate brachytherapy for prostate cancer
63 Reduced unmet supportive care needs after implementation of a prostate cancer Julie Sykes specialist nursing service
64 Improving Patient Outcomes In Robotic Prostatectomy Patients Using A Nurse-Led Emma Birch Clinic
66 Reduction of fatigue in men on ADT for prostate cancer: effect of varying exercise Dennis Taaffe modes
78 Prostate cancer: Impact on quality of life for a cohort of New Zealand men Charis Brown
81 Building systematic access to psychological services for men with prostate cancer Tessa Jones
98 Psychological Distress and Advanced Prostate Cancer Leah Zajdlewicz
111 Maximal exercise testing of men with prostate cancer being treated with ADT Robert Newton
114 Establishment and evaluation of a multidisciplinary complex prostate cancer clinic Helen Crowe age 22 P Posters continued Nursing & Allied Health 120 The efficacy of a clinician referred exercise training program on markers of Patrick Owen cardiometabolic risk for prostate cancer survivors
130 Engaging Men with Prostate Cancer: The evaluation of a tumour specific. Living with David Gray Cancer Education Program
150 Pre-operative Pelvic Floor Muscle Training: a Review Melissa Martin
152 Using web-enabled technology to support men with prostate cancer Addie Wootten
156 The efficacy of a clinician referred supervised exercise training program on fitness, Steve Fraser body composition and physiological outcomes for prostate cancer survivors
163 Validation of a Nurse Led Robotic Prostatectomy Patient Pathway Emma Birch
164 Pelvic Floor muscle contraction with verbal instruction- do men get it? Patricia Neumann
174 Development and testing the acceptability of Rekindle, a web-based psychosexual Zac Seidler resource for all cancer survivors and their partners
175 Qualitative experiences of patients with incontinence Sarah Woollet age 23 P Page 24 133 132 129 127 124 116 115 112 80 48 30 29 13 11 99 60 44 6 168 137 135 123 117 P T growth inprostatecancer YB prostate cancercells Relative cytotoxicpotenciesofalpha1-adrenoceptorantagonistsonPC3andLNCap Monoterpene glycoside,ESK246,targetsLA cancer Characterisation ofAD cancer Circulating microRNAsassociatedwithdocetaxelchemotherapyoutcomeofprostate prostate cancer Overexpression ofAC Prostate Cancer Repositioning "Old"DrugsforNewCauses:IdentifyingT Australian Prostate Cancer BioResource,2014 Clinical StudiesattheAustralianProstate CancerResearchCentreQueensland Defining theeffectofmetformintreatment inandrogendeprivedprostatecancercells Inhibition offattyacidsynthasesuppresses androgensignallinginLNCaPcells large collaborativeoncologicalgeneticsstudies(COGS) Association andfunctionalanalysisofmiRSNPinprostatecancer-Resultfrom the risk F T exosomes Androgen receptorinfluencestheproliferationofprostatecancercellsthrough prostate cancercells BDX1: Anaturalsmallmoleculeactivatoroftheaminoacidstressresponsepathwayin increased byinsulin Androgen deprivationincreasesmigration andinvasioninprostatecancercellsis an Australianendemicrainforesttree Mechanism ofactionstudiesinprostatecancercellsonnewcompoundsisolated from inhibition oftopoisomeraseIIinLNCaPcells The ascidiannaturalproductEBactivatesDNAdamageresponsepathwaysthrough Challenges andOpportunitiesinEstablishingBiobankingfromaBodyDonorProgram 3D BoneMarrowMetastaticProstateCancerNicheMimic Disrupting caveolaepromotesmalignantbehaviourinnormalprostatecells PTRF decreasesprostatecancerangiogenesispotential r argeting neuropilin-1toinhibitprostatecancermetastasisandtherapyresistance o unctional analysisoftheKLK3variants,foundtobeassociatedwithprostatecancer -1, adriverofprostatecancerprogression a s n t s e l r a s SM1,CACNA1D andLMNB1,threenovelbiomarkercandidatesin t AMTS i o c -15: apotentialtumoursuppressorgeneinProstate o n n t a i n u l S e d T3-mediated aminoacidtransportandcell c i e n reatments forMetastatic c e Conference P A 15th r s Esha Shah T Maggie F Jennifer Gunter Martin Sadowski Jyotsna Batra Srilakshmi Srinivasan Brett Hollier Carolina Soekmadji Michelle Liberio Anja Rockstroh Amanda F Eman Mosaad Qian W Marley Binder Hui-Ming Lin Saied Alinezhad Zeyad Nassar Phoebe Sarkar Claire Levrier Michelle Liberio Allison Eckert Jin YihLow o i rina Y a s - t P a t a eadon e c ang i C fi ung orbes a c n 2014 c e r Clinical Urology Meeting Following on the huge success of the Prostate Cancer World Congress in 2013, the Clinical The Asia-Pacic Prostate Cancer Urology Stream at the 2014 Asia-Pacic Prostate Conference program has been reviewed Cancer Conference promises to raise the bar by the Genitourinary Oncology Special Advisory Group (SAG) of the Urological further again. The Melbourne Consensus Statement Society of Australia and New Zealand. on the Early Detection of Prostate Cancer attracted The following CPD pints have been worldwide attention upon its release at the 2013 conrmed: meeting subsequent peer-review publication in the BJUI recently. This year, we again plan to leverage Monday 1 September: off the presence of so many world-leading prostate 7 hours cancer experts to answer some of the key Tuesday 2 September: questions challenging us in clinical practice today. 7 hours Our International Faculty contains a multidisciplinary mix of experts from the world of Additional Breakfast Session urology, medical oncology, radiation oncology, Tuesday 2 September: translational science, nursing and allied health, and 1 hour will address some of the most pressing areas in prostate cancer today including: Total CPD points for the full meeting: 14 points
Ÿ Diagnosis, staging & risk stratication Total CPD points for the full meeting Ÿ Advances in MRI and other imaging including breakfast session Tuesday 2 September: Ÿ Active surveillance 15 points Ÿ Radical prostatectomy - improving outcomes Ÿ Castrate resistant prostate cancer - the da Vinci Masterclass Sunday 31 August: changing paradigm 7 hours Ÿ Advances in radiation oncology LDR Brachy Masterclass In addition to the keynote addresses in the main Sunday 31 August: plenary, we will present breakfast sessions, satellite 5 hours sessions, specialist workshops and the 4th da Vinci Prostate MRI Imaging & Biopsy Prostatectomy Masterclass. Masterclass Sunday 31 August: 5 hours We look forward to presenting another outstanding Clinical Urology Program at APCC 2014 and we in Category 4: thank you for your support. Maintenance of Clinical Knowledge and Skills
Clinical Urology Breakfast Tuesday 2 September 2014 Co Convenor Co Convenor Professor Associate Professor 0645 – 0745 Tony Costello Declan Murphy Sequencing of therapies in metastatic President, Convenor, Clinical Urology prostate cancer: how and when 15th Asia-Pacic Prostate Dr Matthew Smith Cancer Conference Sponsored by Bayer Thank you to the support of our sub Committee Members Dr Ben Tran A/Prof Scott Williams
Royal Melbourne Hospital, Peter McCallum Cancer age 25 P Melbourne Centre, Melbourne Page 26 N Dr PrueCormie,ProfDanielGalvaoandMarkT workshop ledbytheexpertexercisephysiologistsProfRobertNewton, K speaker Highlights oftheprogram latest evidenceinexerciseprescriptionformenwithprostatecancer Cowan University be presentedbyleadingexercisephysiologyresearchersfromEdith conducted. OnMondayafternoonaninteractiveexerciseworkshopwill period sopleasemakesureyouexplorethefantasticworkbeing submitted abstractswillalsobeondisplayfortheentireconference full sessiondedicatedtooriginalresearchpresentations.P submitted forpresentationinthenursingandalliedhealthstreamwitha Monday 1stSeptember metastatic prostatecancer day willprovideaninsightintothecomplexitiesofadvancedand explore thechallengesofhormonaltherapyandnalsession multidisciplinary overviewofactivesurveillance,thethirdsessionwill will focusoncontinencemanagement,thesecondsessionprovidea prostate canceracrossallstagesofthedisease.Theopeningsession multidisciplinary seriesofsessionsfocussedonthecaremenwith Sunday 31stAugust care forpatientsandtheirpartnersfamilies. existing prostatecancermanagementandprovidethebest disciplines usingamulti-disciplinaryapproachcanenhance program willhighlighthowtheprofessionalexpertiseofthese cancer careinafulldayprogram.TheNursing&AlliedHealth to offeracomprehensivemultidisciplinaryapproachprostate exercise physiology nursing, psycho-oncology relevant informationandeducationacrossthedisciplinesof The NursingandAlliedHealthstreamshowcasesthemost ettering CancerCentreinNewY u , DrChristianNelson,ClinicalP r s . Thissessionwillprovideahands-onexperienceofthe i n . Thisyearthesedisciplineswilljointogether g &A . , continencepractitionersand will provideacomprehensive ork; andtheinteractiveexercise
will showcasethebestresearch include ourinternationalguest sychologist fromMemorialSloan l l i e revaskis. d H osters of e a . l t h Royal Melbourne Hospital. department ofurologyatThe Centre andalsoworks inthe research attheEpworth Prostate clinical andalliedhealth Cancer Research;the directorof manager atAustralianProstate W the areaofprostatecancer psychologist whospecialisesin Dr AddieW Cancer Research Manager Centre, eHealthResearch Research, EpworthProstate Director ofClinical&AlliedHealth Royal MelbourneHospital. Department ofUrology Clinical P Dr AddieW Co Convenor with prostatecancer nursing managementofmen won awardsforherworkonthe internationally presented nationallyand as aresearchnurse.Shehas and atEpworthProstateCentre cancer practice, devotedtoprostate employed inaprivateurology organisations inAustralia.Sheis urology nursingprofessional was instrumentalinestablishing urology forover20years,and Helen hasbeenworkingin Prostate Centre Research Nurse,Epworth Urology NursePractitioner Ms HelenCrowe Co Convenor ootten istheeHealthresearch , asaNursePractitioner , AustralianProstate sychologist, ootten isaclinical ootten , publishedand . , The , . Dr N care. her interests inurologicalnursing number of awardsassociated with publications, andhas receiveda education meetings, hasseveral at numerousstateand national Kay hasbeenaninvited speaker Zealand UrologicalNursesSociety Society Victorian UrologicalNurses was afoundingmemberofthe urology &nursingeducation.She special interestsinprosthetics nursing formanyyears.Shehas has beeninvolvedinUrological Australian UrologyAssociatesand Kay isPracticeManagerat Urology Associates Practice Manager/RNAustralian management inprimarycare. interest inProstatecancer Cancer Research,withaparticular Jane isalsoinvolvedwithProstate chronic diseasemanagement. hormone therapyandprovides and monitorstheeffectsof Prostate Cancerandmanages she seesmenwithAdvanced Research Centre,(Epworth)where Australian ProstateCancer Cancer Physician,parttime,atthe Jane startedworkasaProstate suburbs ofMelbourne.In2011 General PracticeintheEastern Jane hasworkedover20yearsin Epworth ProstateCentre Prostate CancerPhysician, Private GeneralPractitioner& Dr JaneCrowe Ms KayT Thank youtothesupportofourSubCommitteeMembers u , andtheAustraliaNew r albot s i n g &A . prostatectomv of incontinencepreandpost the preventionandmanagement She hasaparticularinterestin and malepelvicoordisorders. specialises inmanagingfemale private practicewhich Health Physiotherapy lymphedema. toxicities; management of ability incancerpatients;ADT composition andfunctional decline instrength,body exercise medicineforreducing research directionsinclude: Australia. Currentclinicaland Director ofW years ofexperienceandisthe Rehabilitation. Shehasover20 W Cowen UniversityHealthand and SportsScienceatEdith in ContinenceandP has postgraduatequalications College ofPhysiotherapistsand Shan isafellowoftheAustralian Physiotherapy Women's andMen'sHealth Ms ShanMorrison F Professor RobNewtonis Edith CowanUniversity Prof RobertNewton oundation ProfessorinExercise ellness Institute,P l l i e d H omen's andMen's . erth, W elvic Floor , aVictorian e estern a l t h P Professional Development(CPD) criteria for2Continuing Development offeringmeetsthe certies thatthisProfessional Development Committee The ES about thebenetsofexercise. your prostatecancerpatients knowledge neededtoadvise that willfullyequipyouwiththe lead thisinteractiveworkshop from EdithCowanUniversitywill Prue CormieandMarkT Newton, ProfDanielGalveo,Dr with prostatecancer exercise interventionsformen Learn fromtheleadersin of nursing education. APCC 2014 offers10.5hours F professional development. be countedineachportfolioof professions, thoseactivitiesmay both nursingandmidwifery If CPDactivitiesarerelevantto active learninghavetakenplace. to calculatehowmanyhoursof nurse ormidwife'sresponsibility Location: MelbourneConvention T Date: with prostatecancer prescription formen Latest exercise equal onehourofCPD One hourofactivelearningwill Standard Development Registration Continual Professional of Australia Nursing andMidwiferyBoard ime: ull attendanceatthis oints.
SA Professional Centre 15:30 –17:00 Monday 1September . ProfRob . Itisthe revaskis
Page 27 Page 28 T clinical outcomes. biomarkers couldinuence cancer treatment responseofprostate assessing, andmonitoringthe biomarkers fordiagnosing, session willalsoexplorenew role ofandrogenreceptor migration andinvasionthe surveillance, promotersof Themes includeimmune explored inthissession. growth andmetastasiswillbe prostate cancercelldormancy The mechanismsresponsiblefor and Biomarkers Metastasis, Progression resistance. metastasis andtreatment response, inhibitionof cancer targeted therapiesforprostate this sessionwillexplorenovel newly isolatednaturalproducts, F New Therapies be themed-basedandcoverthefollowingareas: clinical researcherstoimproveoutcomesforpatients.Sessionswill cancer researchers,linkingresearchfrombasic,translationaland The translationalsciencemeetingbringstogetherleadingprostate rom “old”drugsthroughto r a , andhowthese , biomarkersoftreatment n s l a t i . The o , n a associated withprostatecancer of geneticriskfactors This sessionpresentsanumber Genetics andEpigenetics Prostate Cancer intervention. potential targetsfortherapeutic session exploresanumberof targets forfuturetherapies.This migrate andinvadeprovides cells tosurvive,proliferate, The abilityofprostatecancer Therapeutic T recurrence andmetastases. prostate cancerprogression, changes associatedwith genomic andepigenetic and anin-depthanalysisofthe l S c i e n argets c e P , r o 2007 to2013 Research Programfrom Australia (PCF Cancer F was ChairoftheProstate appointments, andhe P at T Research &Development He istheDirectorof including prostatecancer research interests scientist withseveral recognized physician- Is aninternationally Prof JohnMills Co-Convenor pharmaceutical industry projects inthe programs andR&D academic research in managingboth David bringsexperience Melbourne Australia Epworth ProstateCentre, Chief OperatingOfcer Dr DavidSandall Co-Convenor athology issuP g r ath Specialist oundation of , amongother a A) m - , . Masterclasses
MASTERCLASS 4th da Vinci c Prostatectomy Masterclass This event has attracted large numbers of delegates in recent years to hear from world Convenors experts in robotic-assisted surgery and has proved one of the most highly-rated parts of the Program. The rapid growth in installation and procedure numbers since 2011 has led to a doubling in the number of systems available and a huge increase in the number of urologists transitioning to robotic-assisted surgery. This Masterclass remains the premium event for surgeons at all levels to hear from the best in the world and to improve their techniques.
This year we have assembled a hugely-experienced faculty of robotic surgeons to deliver an outstanding program for those interested in robotic-assisted radical prostatectomy Dr Geoff Coughlin using the da Vinci© surgical system. Dr Henk Van Der Poel (NKI, Amsterdam), Dr John Davis (MD Anderson, Texas) and Dr Markus Graefen (Martini Clinic, Hamburg) are world- leading experts in robotic cancer surgery and will lead the faculty in an all-day Masterclass focusing this year on more advanced aspects of the procedure. Urologists of all levels from trainee to experienced robotic surgeon will benet from this interactive and video-based da Vinci Prostatectomy Masterclass.
Highlights include: Dr Daniel Moon Ÿ Full-length da Vinci© radical prostatectomy and extended PLND (Henk Van Der Poel), including uorescence-guided sentinel node dissection Ÿ Creating Spaces – technical tips for difcult situations (John Davis) Ÿ Urethral dissection, apex preparation & frozen section biopsy – tips for maximizing functional outcomes (Markus Graefen) Ÿ Video-based tutorials of difcult cases Ÿ Full schedule to be conrmed
In addition, a da Vinci© Si with simulator will be available all day in the trade area. Associate Professor Declan Murphy Program 8:30 – 10:30 SESSION 1 Chairs: Geoff Coughlin and Daniel Moon Unedited case - High risk prostate cancer | Henk van der poel Evidence for RARP – key robotic surgery publications from 2013-14 | Simon van Rij 10:30 – 11:00 Morning tea 11:00 – 12:30 SESSION 2 - Maximising Functional Outcomes Chairs: Peter Sutherland and Justin Peters 11:00 – 11:20 Bladder neck preservation | Markus Graefen 11:20 – 12:10 Nerve-sparing in 2014 – how I do it | Henk van der poel, John Davis, Geoff Coughlin 12:10 – 12:30 Managing urethra/apex | Markus Graefen 12:30 – 13:30 Lunch 13:30 – 15:00 SESSION 3 - Tips and Tricks “Creating spaces” Chairs: John Yaxley and Laurence Harewood John Davis 15:00 – 15:30 Afternoon tea 15:30 – 17:00 SESSION 4 - High risk prostate cancer Chairs: David Bouchier-Hayes and Nathan Lawrentschuk 15:30 – 16:00 Extended pelvic lymphadenectomy | John Davis 16:00 – 16:20 Sentinel nodes | Henk van der Poel 16:20 – 16:50 Salvage RARP post HIFU/focal therapy - UCL Experience | Paul Cathcart
16:50 – 17:00 Discussion age 29 P Page 30 M P M 15:30 –16:00 15:15 –15:30 15:00 –15:15 14:00 –15:00 13:30 –14:00 12:45 –13:30 12:30 –12:45 11:45 –12:30 11:30 –11:45 11:00 –11:30 10:35 –11:00 prostate imaging. widely atlocalandnationalmeetingson 10:05 –10:35 peer teaching prostateimaging.Heispublishedin Royal MelbourneHospitalandisinvolvedin He establishedtheprostateMRIserviceat image-guided biopsy MRI andhasbeenapioneerintheuseofstandardizedreportingmethodology(PIRADS)also the Netherlands.ProfessorBarentszisworld'sleadingauthorityonprostateimagingusingmultiparametric Professor JelleBarentsz,andHeadofProstateImagingattheRabdoudUniversityMedicalCentrein T guided ultrasoundapproachtoprostatebiopsy modality interest. Theincreasedavailabilityof3Tmagnetsandappropriateexpertisehasledtousethis The useofMRIscanningforthediagnosisandstagingprostatecancerhasbecomeanareaconsiderable 10:00 –10:05 Program o improveourknowledgeinthisarea,wearepresentingaProstateMRIImaging&BiopsyMasterclassledby A -reviewed journalsandhaspresented r a S o . ImprovedimagequalityhasalsoledtotheuseofmultiparametricMRIimagesaspartafusion- T s s E t R t e Body ImagingF Cancer Centeraspartofa at MemorialSloanKettering with professorHedvigHricak Stefan learntprostateMRI Royal MelbourneHospital Deputy DirectorofRadiology A/Prof StefanHeinze Co-Chair C a Lecture and Closingcomments | Problem casesreview withfaculty| Afternoon T W Lectures | Lunch Case reviewwithfaculty| W Case reviewwithfaculty| W CADSTREAM orientation&HowIreportaprostateMRI| Lecture | W r orkstation basedcase review| orkstation basedcasereview| orkstation basedcasereview| elcome /Courseoverview| L . t A c e M S l a Jelle Barentez S P ea eter Swindle s ellowship. s R I All faculty All faculty , m . Declan Murphy a Private HospitalandtheW Mater PrivateHospital,AdultsGreenslopes Research Instituteaswellclinicalappointmentsatthe HehasaresearchappointmentattheMaterMedical Brachytherapy F the prostate.HealsocompletedanAmerican prostate cancerandundertook2yearsresearchonMRIof Sloan-K undertook a2yearsubspecialtyF Sydney onmagneticresonanceoftheprostate.Hethen completed aMastersofSurgeryattheUniversity DrSwindletrainedinQueenslandandsubsequently Self Self Self Jelle Barentez, StephanHeinze All faculty g -review -review -review i ettering CancerCentreinNewY n , StephanHeinze g &B ellowship attheSeattleProstateInstitute. MBB Dr P Co-Chair Dr P specialises solelyinprostatecancer the prostate. and hehasaspecialinterestinMRIof expertise liesinroboticprostatectomy eter Swindleisaurologistwho eter Swindle S MSFRAC Stephan Heinze esley Hospital. i o ellowship atMemorial p S s Conference P A 15th ork focusingon r s o i y a s - t P a t a e c i C fi a c . His n 2014 c e r MASTERCLASS Focal therapy: the role of LDR & HDR brachytherapy
The aim of this masterclass is to bring together experts in the eld of Faculty brachytherapy, focal therapy, imaging and pathology to present the evidence for developing a focal brachytherapy program. The workshop A/Prof Juanita Crook will include discussions on focal therapy alone for early low risk prostate cancer, focal boosts in whole gland monotherapy and salvage of focal A/Prof Jeremy Millar recurrences. A/Prof Nathan Lawrentschuk Workshop aims Dr David Clouston Ÿ To introduce the concept of focal distribution of cancer in the prostate, Dr James MacKean Ÿ To review the evidence for imaging modalities to identify signicant focal lesions, Dr John Yaxley Ÿ To explore the role of brachytherapy in delivering focal therapy. A/Prof Scott Williams Who should attend All those having an interest in the management of prostate cancer: A/Prof Annette Haworth Ÿ Radiation oncologists Ÿ Urologists Ÿ Radiologists Ÿ Physicists Ÿ Radiation therapists
Program 10:30 – 11:10 The evidence for focal therapy A/Prof Juanita Crook, University of British Columbia, BCCA Center for the Southern Interior 11:10 – 11:30 Pathology and natural history of prostate cancer Dr David Clouston, Anatomical Pathologist, TissuPath 11:30 – 12:30 MRI for focal brachytherapy Dr James MacKean, Radiation Oncologist, & Dr John Yaxley, Urologist, Genesis Cancer Care, The Wesley Hospital, Brisbane 12:30 – 13:30 Lunch 13:30 – 14:00 Co-registration of imaging studies, the pros and cons of rigid vs. deformable registration A/Prof J Crook 14:00 – 14:20 Is there a gap in health care in Australia that focal brachytherapy can ll? A/Prof Jeremy Millar, Director, Radiation Oncology, WBRC & WBRG, Alfred Health 14:20 – 15:00 Treatment options for focal therapy A/Prof Nathan Lawrentschuk, U. Melbourne, Dept of Surgery and Ludwig Institute for Cancer Research, Austin Hospital and Peter MacCallum Cancer Centre 15:00 – 15:30 Afternoon tea 15:30 – 16:00 Treatment response following focal therapy, when do we know we have succeeded? A/Prof Scott Williams, Radiation Oncology, Peter MacCallum Cancer Centre, U. Melbourne 16:00 – 17:00 Are we ready for a focal brachytherapy trial in the Asia-Pacic Region? Proposer: Dr Ana Fernandez-Ots Discussant: A/Prof Juanita Crook Panel discussion: A/Prof Juanita Crook, A/Prof Jeremy Millar, A/Prof Nathan Lawrentschuk, Dr David Clouston, Dr James MacKean, Dr John Yaxley, A/Prof Scott Williams,
A/Prof Annette Haworth age 31 P Page 32 S Ÿ Ÿ the followingcategories: Prizes willbeawardedineachof presenters abouttheirwork. Ÿ Cancer research inallareasofProstate the exhibitionandseelatest Delegates arewelcometoroam Space ongroundlevel. be servedintheExhibition Cocktail drinksandcanapéswill
V T Date: P W ime: enue: oster ViewSession elcome Receptionand T Clinical Urology Nursing &AlliedHealth
o ranslational Science . T c Centre, GroundFloor Melbourne Convention 5.00pm –7.00pm Sunday 31August,2014 alk oneonwith i a l P r o g r Date: Conference Dinner T V Satellite Symposium Centre (SouthWharfEntrance)followingtheJanssen Coach transferswilldepartfromtheMelbourneConvention Getting There: ballroom. Orperhapsit'sbecauseyouare. the illusionthatyouarecelebratinginalavishEuropean commodes thatdancelightaroundtheroom,create parquet ooringorthe18thcenturystylemirrored Dress: to anotherworld.P T a ake onestepinsideMuralHallandyouwillbetransported ime: enue:
Enter via P m ostal Lane > Monday 1September 7:00pm –11:30pm Mural Hall,Myer Lounge Suit erhaps itistheP Ÿ Ÿ Ÿ Directions: , 2014 T sign todirectyou will beattheentrancewitha A MuralHallStaffmember Little BourkeStreet Enter viaP ake theliftstoLevel6 arisian inspiration,the ostal Laneoff Conference P A 15th r s o i a s - t P a t a e c i C fi a c n 2014 c e r Registration Information
Consultant/Trainee/ Scientist/Researcher/ Masterclass Only Registrar/Fellow Full Student/Post Doc Full Registration includes: Registration includes: Registration includes: Ÿ Entry to nominated Ÿ Entry to all conference Ÿ Entry to all conference Masterclass sessions (Sunday sessions (Monday Ÿ Morning and Afternoon Tuesday) Tuesday) Teas and Lunch on Ÿ Morning and Afternoon Ÿ Morning and Afternoon Sunday 31 August Teas and Lunch Daily Teas and Lunch Daily Ÿ Entry into the Exhibition Ÿ Attendance to either the Ÿ Attendance at the Area on Sunday 31 da Vinci Masterclass or Welcome Reception & August LDR Brachytherapy Poster Viewing (Sunday Ÿ Delegate Satchel Masterclass (Sunday 31 31 August) Ÿ Final Program August) Ÿ Entry into the Exhibition Ÿ Attendance at the Ÿ Attendance at the Area (Monday Tuesday) Welcome Reception & Welcome Reception & Ÿ Delegate Satchel Poster Viewing Poster Viewing (Sunday Ÿ Final Program 31 August) Ÿ Entry into the Exhibition Day Registration Registration Desk Area includes: Hours Ÿ Delegate Satchel Ÿ Entry to all conference The Registration Desk will be Ÿ Final Program sessions on day of open during the following Registration hours: Nursing & Allied Health Ÿ Morning and Afternoon Full Registration Teas and Lunch on day of Sunday 31 August includes: Registration 07:00 - 17:30 Ÿ Entry to all conference Ÿ Entry into the Exhibition Monday 1 September sessions (Sunday Area on day of 07:00 - 17:30 Monday) Registration Ÿ Morning and Afternoon Ÿ Delegate Satchel Tuesday 2 September Teas and Lunch Daily Ÿ Final Program 06:45 - 16:00 Ÿ Attendance at the Ÿ Attendance at the Welcome Reception & Welcome Reception & Poster Viewing (Sunday Poster Viewing (Nursing 31 August) & Allied Health Sunday Ÿ Entry into the Exhibition Tickets Only) Area (Sunday Monday) Ÿ Delegate Satchel Ÿ Final Program Ÿ Option to purchase a conference upgrade to include Tuesday Conference attendance for an additional $100.00 age 33 P Page 34 I P hours priortotheirscheduledpresentation. Speaker's Preparationroomaminimum 2 presentation withtheA Speakers arerequestedtoloadtheir T Monday 1September Sunday 31August open duringthefollowinghours: Melbourne ConventionCentreandwillbe to theRegistrationDeskinfoyerof The Speakers'Preparationroomisadjacent Speakers' PreparationRoom August. Session from17:00-19:00onSunday31 present attheirposterduringtheP T Desk priortosettinguptheirpostersinthe presenters mustcheck Conference onT August throughtotheconclusionof P P Room toassistwiththisprocess. be availableintheSpeakers'Preparation presentation. Anaudiovisualtechnicianwill presentation thedaybeforetheir morning sessionshouldcheck Speakers whoarepresentingatanearly commencement oftheirallocatedsession. Room atleasttwohourspriortothe presentation intheSpeakers'Preparation It isimportantthatallspeakersuploadtheir Oral Presentations to thestartofsession. presentation roomatleasttenminutesprior Please ensurethatyouareavailableinyour Chairs andSessionModerators n uesday 2September rade area.Thepresentingauthormustbe osters willbedisplayedfromSunday31 oster Presentations r f o e r s m e uesday 2September n a t -in attheRegistration V T t
a echnicians atthe i o t -in their n i o 0700 –1530 0700 –1730 0700–1730 oster n . P oster M Y o u e r H 4 Melbourne Convention and ExhibitionCentre l b o s o 1 t C
LA TROBE ST u i
LITTLE LONSDALE ST t
r
ST
SOUTHERN CROSS SOUTHERN y A
Melbourne Convention TION LONSDALE ST n
and Exhibition Centre KING LITTLE BOURKE ST SPENCER STREET SPENCER
BOURKE ST e
LITTLE COLLINS ST
COLLINS ST
FLINDERS LANE
KING ST KING CLARENDON 2
Y arra Promenade
WHITEMAN STREET Crown Entertainment ST WILLIAM Complex
Y a r Y arra Promenade
WHITEMAN STREET Crown Entertainment ST WILLIAM Complex
Y a rr a Enterprize Park
R i ST MARKET v e 3 r
QUEENS BRIDGE 5 CITY ROAD HARDW
ARE QUEEN ST QUEEN
POWER ROAD POWER Banana Alley SOUTHBANK Southbank Promenade
BOURKE ST MALL GPO
ELIZABETH ST ELIZABETH BOULEV
FLINDERS STREET
Flinders W
ST ARD
A
TION
Y SW a alk W STREET ANSTON r r a
Myer Building Conference Dinner
R i ALK
v
er Mural Hall
Federation FLINDERS ST
Princes W Square RUSSELL ST ST RUSSELL RUSSELL
alk EXHIBITION ST EXHIBITION T Southbank Whiteman Streets, Cnr Queensbridgeand Melbourne Crown Promenade Southbank Whiteman Streets, Cnr ClarendonStreetand Melbourne Crown Metropol South Wharf 2 ConventionCentrePlace, (Conference Hotel) South Wharf Hilton Melbourne Accommodation Melbourne 60 MarketStreet, Oaks onMarket Docklands 66 AuroraLane, ravelodge Docklands 5 4 3 2 1
Page 35 Page 36 G E F P Hawthorn VIC3122 PO Box170 ICMS PtyLtd Conference Ofce meal. require aspecialdietary cater fordelegateswho setup intheExhibitionto A separatebuffetwillbe be servedintheExhibition. your registrationfeeandwill conference areincludedin and afternoonteasduringthe All morningteas,lunches Catering and adjacentcarparks. Melbourne ExhibitionCentre P Car P [email protected] or contact staff attheregistrationdesk conference. Pleaseseethe available uponrequestpost A certicateofattendanceis Attendance Certicate : arking isavailableatthe : : [email protected] +61398187111 1300792466 e arking n e r a l I n f o breaks. message boardduring are requestedto check the registration desk. Delegates board, locatednexttothe be postedonthemessage Conference. Messageswill for delegatesduringthe desk staffwilltakemessages The Conferenceregistration Messages before enteringsessions. silent modeorswitchedoff phones andpagersarein request thatallmobile and otherdelegates,we As acourtesytospeakers and P Mobile Phones personal insurance. arrangements withrespectto should maketheirown or/accompanying persons belongings. P luggage and/orpersonal for lossordamagetotheir accompanying person,nor participants and/or nature incurredby injuries/losses ofwhatever accept noliabilityfor the HostOrganisations Conference Committeeand Conference Ofce,the accompanying persons.The participants and/or loss ofmoniesincurredby accept noresponsibilityfor the HostOrganisations Organising Committeeand the ConferenceOfce, unforeseen circumstances, disruption orother In theeventofindustrial Liability Disclaimer r m agers a articipants and t i o n T APCR BusinessCentreinthe Business Centre.Visitthe Exhibition andinthe of chargethroughoutthe WIFI accessisavailablefree WIFI Registration Desk. see thestaffat you wishtoattend,please received ticketsforfunctions your ticketsorhavenot holder included inyournamebadge and Conferencedinnerare masterclasses, breakfasts Y T Conference venue. Victoria, includingthe and restaurantsthroughout public buildingsandhotels that smokingisbannedin Delegates shouldbeaware No SmokingP name badgeatalltimes. Exhibition. Pleasewearyour Conference sessionsandthe entrance tickettoall Y Name Badges computers. rade Areatousethe our ticketsforthe our namebadgeisyour ickets . Ifyouhavemisplaced Conference P A 15th r s o i a s - t P a olicy t a e c i C fi a c n 2014 c e r E T Société Internationaled’Urologie (SIU) Scanmedics Sano Prostate CancerF Olympus Australia Neotract AustraliaPtyLtd N. Stenning&Co. Meditron PtyLimited Karl StorzEndoscopy Janssen IPSEN PtyLtd Innologic Imaging Solutions F Device T Coloplast Bayer Australian ProstateCancerResearch AstraZeneca Astellas AMS Australia Amgen following hours: Centre andwillbeopenduringthe F The ExhibitionislocatedinMain Abbvie PtyLtd Exhibitors olmar Australia erring Pharmaceuticals oyer oftheMelbourneConvention x h
19&20
echnologies i b i
t oundation ofAustralia i o
n I n
f o
BusinessCentre
r m
2&3
4&5
6&7
a T Monday 1September Sunday 31August uesday 2September t i 24 21 23 1 14 18 12 9 22 29 16 11 25 26 17 27 10 8 28 o n
0900 –1530 0900 –1700 1000 –1900
Page 37 Exhibition Information continued
N O I T A R T S I G E R Y R T N E
S Y A L P Bu S s I C ine 9 e s D nt s 2 R g re n n
E i io r
T t e a t
S t a
O S P C 8 2
P
U H H g 1 n n i io r t e
a t t H a
S C H 2 3 7 4 2 5 8 T I X E / Y R n e T e io t ff N 6 a o t E 2 C S 9
P
U 0 g 5 n 1 n i io r 2 t e a t t a 1 S C 1 3 2 2 1 2 4 2 4 2 1 1 2 0 2 9 6 1 7 1 1 8 1 age 38 T I P X E E potential. developing apipelineofmedicineswith breakaway reached millionsofpatientsaroundthe worldandis biotechnology pioneersince1980,Amgen has delivering innovativehumantherapeutics.A by discovering,developing,manufacturingand biology forpatientssufferingfromseriousillnesses Amgen iscommittedtounlockingthepotentialof stand andwww clinicians &theirpatients.VisitusattheAbbVie innovative waysAbbVieishelpingsupport W W pharmaceutical leader expertise &structureofalongestablished combines focus&passionofaleadingbiotechwith AbbVie isanew&differentkindofcompanythat Email W F Email T F T
Address Address Contact Abbvie PtyLtd Contact Amgen ST ST elephone elephone acsimile acsimile e’d liketotellyoumoreaboutthecreative& ebsite ebsite AND 28 AND 8 x h i b www [email protected] www +61 298701344 [email protected] +61 298701333 +61 290358601 +61 290358600 North R NSW 2019Australia Level 7,123EppingRoad 32-34 LordStreetBotany T Anne Sullivan essa James .abbvie.com i .amgen.com.au .abbvie.com.au t yde NSW2113Australia . o r P r o f i l e s Zealand forthelongterm. numerous practicesthroughoutAustraliaandNew dedication seesusprovidingatruepartnershipin surgery support,staffknowledgeand and femaleurology W Zealand coveringprostheticurology to UrologiststhroughoutAustraliaandNew provide qualitysolutionsandunmatchedresources AMS Australiautilisesthisglobalstrengthto devices thatrestoremaleandfemalepelvichealth. developing, manufacturingandmarketingmedical AMS istheworld’sleadingcompanyfocusedon W Email F T F T Address
Address Contact Australia PtyLtd Astellas Pharma Contact AMS Australia ST ST elephone elephone acsimile acsimile ebsite ebsite AND 19&20 AND 10 + 61298141120 www [email protected] +61 294276296 www + 61298141100 +61 294256800 NSW 2066Australia Unit31F MacquarieP Suite 4,Level6EdenP Michelle Commane P at Callanan .astellas.com.au .americanmedicalsystems.com . Ourtraininginitiatives,in , 16MarsRoadCoveW ark. NSW2113Australia , BPHsolutions ark Drive, est
Page 39 15th Asia-Pacific Prostate Cancer Conference 2014
STAND 27 STAND 17
AstraZeneca Coloplast Australia Contact Desi Mavros Contact Simone Holst Address 33 Gilby Road Mt Waverley Address 5 Alma Road North Ryde VIC 3149 Australia NSW 2113 Australia Telephone 0403 551 239 Telephone +61 2 9978 3500 Facsimile +61 3 9541 1199 Facsimile +61 2 9978 3700 Email [email protected] Website www.astrazeneca.com.au Website www.coloplast.com.au
AstraZeneca Australia, based in North Ryde, Coloplast Porges is a leading global manufacturer Sydney, is the largest pharmaceutical company and marketer of innovative medical devices for the operating in Australia. AstraZeneca employ almost management 1,000 people, are one of the country’s largest manufacturers of medicines and are a key exporter and treatment of urological conditions to include to 35 international markets. AstraZeneca incontinence, pelvic organ prolapse, Peyronie’s manufactures 100 separate product lines, namely Disease and ED. Products include: sterile respiratory and local anaesthetic products. Titan®/Genesis® penile prostheses, Virtue® male Of the top twenty medicines used in Australia, four sling, Torosa®/KiWeeTM testicular prostheses, are made by AstraZeneca. AstraZeneca produces Restorelle® mesh, Aris®/Supris™/Altis™ sling medicines in six separate therapeutic areas systems, BoNee® bladder injection needles. including cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory inammation. AstraZeneca contributes signicantly to clinical trials in Australia with approximately 30 concurrent trials in 190 sites across the country.
Business Centre
Australian Prostate Cancer Research Contact James Garland Address Locked Bag 10, East Melbourne, 8002, VICTORIA Telephone +61 3 9421 0985 Email [email protected] Website www.prostatecancerresearch.org.au
Australian Prostate Cancer Research is a national research organisation that partners with leading institutions to develop, fund and deliver national research programs. We are committed and driven to discover new tests, new treatments and to educate the industry on all aspects of diagnosis, treatment and patient care. age 40 P STAND 26 STAND 25
Device Ferring Technologies Pharmaceuticals Contact Marta Orczykowska Contact Gretchen Pryba Address 1 Garigal Road Belrose Address PO Box 135 Pymble NSW 2085 Australia NSW 2073 Australia Telephone 1800 429 551 Telephone 1800 33 77 46 Facsimile 1800 999 323 Facsimile +61 2 9497 2399 Email [email protected] Email [email protected] Website www.device.com.au Website www.ferring.com.au
Founded in 1992, Device Technologies is an Ferring Pharmaceuticals is a Swiss-based established distributor of quality and research-oriented pharmaceutical company that technologically-advanced medical equipment and specialises in products in the eld of consumables. The company is Australian-owned Urology/Oncology, Gastroenterology, and employs more than 500 healthcare specialists Endocrinology and Reproductive Health. At this and support staff in Australia and New Zealand. meeting, Ferring Pharmaceuticals is featuring FIRMAGON® (degarelix), a GnRH receptor Ÿ All products are professionally supported by antagonist. Visit us at the Ferring stand to learn qualied Product Managers and specialists, about FIRMAGON® and its reconstitution and trained to work in surgical and operating room administration process. environments. Ÿ Clinical Educators provide accredited training, in-servicing and ongoing clinical support. STAND 11 Ÿ Technical Service personnel service and maintain our extensive range of capital equipment. Imaging Ÿ Regulatory Affairs ensure all products are Solutions correctly listed with the TGA. Contact Renee Campbell Company Mission Statement: Address PO BOX 1768 Sunnybank Hills To enable superior health outcomes for patients, by QLD 4109 providing access to the best medical systems Telephone +61 7 3209 9712 available worldwide Facsimile +61 7 3209 9812 Email [email protected] Website www.imagingsol.com.au
Imaging Solutions is a healthcare imaging equipment products and consumables supplier. Our critical point of difference is our "single source supplier" philosophy which allows us to offer unmatched convenience and value for money to all our customers. Imaging Solutions offers an extensive range of world-market-leading, rst quality, high performance products which assist our customers in delivering outstanding radiographic diagnostic quality rst time, every time. age 41 P 15th Asia-Pacific Prostate Cancer Conference 2014
STAND 16 STAND 29
Innologic Janssen Contact Dale Johnston Contact Jacqui Wade Address 6 Gould Street, Herdsman Business Address 66 Waterloo Road Macquarie Park Park, Osborne Park WA 6017 NSW 2113 Australia Telephone 1300 729 069 Telephone +61 2 9815 3380 Facsimile +61 2 8583 3333 Facsimile +61 2 9475 0316 Email [email protected] Email [email protected] Website www.innologic.com.au Website www.janssen.com.au
Innologic’s focus is innovation in healthcare Janssen Pharmaceutical Companies of Johnson & combined with exceptional customer service. Johnson are dedicated to addressing and solving the most important unmet medical needs of our Each device in our range was selected for its time, including oncology (e.g. multiple myeloma, quality, reliability, & ability to support the needs of Prostate, Ovarian and Breast cancer), immunology busy clinics. We are focused on being the preferred (e.g. psoriasis), neuroscience (e.g. schizophrenia, supplier of equipment, technical service & dementia and pain), infectious disease (e.g. associated clinical support for our customers. HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes).
STAND 4 & 5 STAND 22
IPSEN Pty Ltd Karl Storz Contact Kelly Gillin Endoscopy Address Level 2, Building 4, Brandon Ofce Contact Amanda Silverstone Park, 540 Springvale Road Address Annex Building, 15 Orion Road Glen Waverley VIC 3150 Australia Lane Cove West NSW 2066 Australia Telephone +61 3 8544 8100 Telephone +61 2 9490 6700 Facsimile +61 3 9562 5152 Facsimile +61 2 9420 0695 Email [email protected] Email [email protected] Website www.ipsen.com.au Website www.karlstorz.com
Ipsen provides specialty medicines and quality KARL STORZ has established itself worldwide as services to Healthcare Professional and their an international and highly regarded company in patients suffering from debilitating diseases. the production and sale of endoscopic devices, documentation and cameras. The majority of At Ipsen, our passion is improving the lives of manufacturing is carried out in Tuttlingen, Germany patients. We do this by working together to build where the art of instrument making is alive and well. partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored We will be showcasing the newest products to the solutions through our agility and innovation and we market, including CMOS Video Cystoscope, 7Fr strive to be even better tomorrow than we are semi rigid ureteroscope, Green Light Laser today. Telescope and High Flow Sheath and UROMAT EASI, the newest Fluid Management System on the Ipsen Pty Ltd is the Australian afliate of a global R market. & D focused pharmaceutical company. age 42 P STAND 9 STAND 18
Meditron Neotract Pty Limited Australia Pty Ltd Contact Michael Fehrmann Contact Tracee Stannard Address PO Box 4230 Ringwood Address Unit 13 76 Reserve Road Artarmon VIC 3134 Australia NSW 2064 Australia Telephone +61 3 9879 6200 Telephone +61 2 9436 0487 Facsimile +61 39879 6244 Facsimile +61 2 9475 4558 Email [email protected] Email [email protected] Website www.meditron.com.au Website www.neotract.com
Meditron supply the complete range of Dornier NeoTract, Inc. is dedicated to developing MedTech products. These include Lithotripters, innovative, minimally invasive and clinically effective Urotables, Holmium Stone Laser and the UroBeam devices that address unmet needs in urology. Our laser for BPH. initial focus is on improving the standard of care for patients with BPH using the UroLift® System, a Meditron also offers technology for MRI-Fusion and minimally invasive permanent device designed to intelligent Perineal Prostate Biopsies. treat LUTS. Learn more at www.UroLift.com.
Furthermore, Meditron distribute CIVCO transducer covers and needle guides for TRUS-procedures. STAND 2 & 3
STAND 12 Olympus Australia N. Stenning & Co. Contact Jada Tomas Contact Derek Foltin Address 3 Acacia Place, Notting Hill VIC 3168 Address 174 Parramatta Road Camperdown Telephone +61 3 9271 5513 NSW 2050 Australia Facsimile +61 3 9562 6416 Telephone +61 2 8594 9100 Email [email protected] Facsimile +61 2 8594 9188 Website www.olympusaustralia.com.au Email [email protected] Olympus is an innovative technology and service Website www.nstenning.com.au provider, excelling in the eld of Urology. With the complete product portfolio in Urology offering N. Stenning & Co. has been proudly selling unique video scopes and bipolar PlasmaButton innovative equipment for over 60 years in the Vaporisation in addition to our range of medical devices industry. Featured will be our Hem- Endourology consumable products, we are the o-lok ligating clip system, Storz Medical ESWT and company to partner with for your daily diagnostic ESWL, and other medical devices specically for and therapeutic requirements. prostate surgery. age 43 P 15th Asia-Pacific Prostate Cancer Conference 2014
STAND 14 STAND 1
Prostate Cancer Sano Foundation of Australia Contact Contact Marieke Koets Address Talavera Corporate Centre 12 – 24 Address Level 3, 39 Chandos Street Talavera Road Macquarie Park St Leonards NSW 2065 NSW 2133 Australia Telephone +61 2 9438 7095 Telephone +61 2 8666 2000 Facsimile +61 2 9438 7099 Facsimile +61 2 8666 3000 Email [email protected] Website www.sano.com.au Website www.prostate.org.au The ambition of Sano is to become a diversied global healthcare leader, focused on patients’ Prostate Cancer Foundation of Australia (PCFA) is needs, the largest pharmaceutical company in a broad-based community organisation and the Europe and in emerging markets, Sano is the peak national body for prostate cancer in Australia. fourth largest worldwide. The Group’s vaccine We are dedicated to reducing the impact of division, Sano Pasteur, is the world leader for prostate cancer on Australian men, their partners, human vaccine production and commercialisation. families and the wider community.
We do this by: Ÿ Promoting and funding world leading, STAND 23 innovative research into prostate cancer Ÿ Implementing awareness campaigns and Scanmedics education programs for the Australian Community, health professionals and Government Contact Paul Blewitt Ÿ Supporting men and their families affected by Address Unit 6 15-17 Gibbes Street prostate cancer through evidence-based information and resources, support groups and Chatswood NSW 2067 Australia Prostate Cancer Specialist Nurses Telephone +61 2 9882 2088 Facsimile +61 2 9882 3549 PCFA receives Government funding for specic projects and relies on the generosity of individuals, Email [email protected] the community and partnerships, such as those Website www.scanmedics.com with the Movember Foundation and Commonwealth Bank, to carry out our essential Scanmedics has been the provider of BK Medical work. ultrasound solutions for over 18 years in Australia and New Zealand. Founded in 1996 by MaryAnne Taylor and David Gibson, the Scanmedics team has attained a reputation for working with clinicians to support patient centred care while improving their clinical outcomes. BK Medical’s superior image quality with Quantum+ technology makes a diagnostic difference to prostate imaging. age 44 P STAND 21 STAND 24
Société Tolmar Internationale Australia d’Urologie (SIU) Contact Michael Sapurmas Address 1155 University Street, Suite 1012 Address Building 2 Level 2 Suite 4, Montreal, QC H3B 3A7 Canada 20 Bridge St Pymble NSW 2073 Telephone +1 514 875 5665 Telephone +61 2 9440 6700 Facsimile +1 514 875 0205 Facsimile +61 2 9440 6750 Email central.of[email protected] Email [email protected] Website www.siu-urology.org Website www.tolmar.com.au
The Société Internationale d’Urologie (SIU) prides New uro-oncology player Tolmar Australia is well itself on fullling the educational needs of its resourced and motivated to support real members, and on mobilizing technology to reach improvements in the quality of life for men with the greatest numbers of urologists worldwide. In prostate cancer. The company sponsors an October 2014, the SIU launched its virtual platform innovative in-home injection service, Eligard® enabling the SIU Congress to go hybrid. Visit NurseCARE (independently run by AESIR Health), Booth # 21 to learn more about our 35th congress that aims to ease the treatment experience. in Melbourne, Australia, Oct. 15 – 18, 2015. Visit us TOLMAR is actively looking to fund researchers to at: www.siu-urology.org for more information on the encourage further advancements. With a different facets of the SIU. collaborative mindset, Tolmar Australia is also a proud sponsor of the Prostate Cancer Foundation of Australia.
Join the conversation on Twitter! Follow @AustProstate and #apcc14 for latest updates age 45 P 15th Asia-Pacific Prostate Cancer Conference 2014
www.prostatecancerconference.org.au
Australian Prostate Cancer Research
Follow us on twitter #apcc14 @AustProstate